Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $297.90
    -7.33 (-2.40%)

    Market Cap: $9.05B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Krystal Biotech Inc (KRYS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Krystal Biotech (KRYS) to earn $8.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $497.46M. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $9.23.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy18.3%
    Buy1083.3%
    Hold18.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 15.2% and revenue estimates rise 27.6%.

    Fiscal year ending Dec 31, 2026
    $8.01
    EPS consensus, revenue $497.46M
    Fiscal year ending Dec 31, 2027
    $9.23
    EPS consensus, revenue $634.85M
    Next report
    Feb 15, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$8.01$7.46 to $10.489$497.46M$494.00M to $500.20M9
    Dec 31, 2027$9.23$7.16 to $11.9711$634.85M$595.30M to $680.80M10

    Quarterly Estimates

    The EPS consensus falls from $2.09 for the quarter ending Dec 31, 2026 to $2.08 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.09$1.75 to $2.5414$137.50M$128.46M to $144.10M13
    Mar 31, 2027$2.08$1.80 to $2.524$139.42M$134.40M to $144.10M5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202714
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 3.0% from $7.78.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$8.01$7.59$7.87$7.87$7.78+2.9%
    Fiscal year ending Dec 31, 2027$9.23$8.95$9.32$9.40$9.32-1.0%
    Quarter ending Mar 31, 2027$2.08$2.16$2.23$2.23$2.23-6.6%

    Frequently Asked Questions About KRYS

    What is the KRYS stock forecast?

    Consensus analyst estimates put Krystal Biotech's EPS at $8.01 for the fiscal year ending Dec 31, 2026, on revenue of $497.46M. The consensus rating from 12 analysts is Buy.

    How do analysts rate KRYS stock?

    Of 12 analysts covering Krystal Biotech, 1 rates it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from KRYS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.01, with estimates from $7.46 to $10.48 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.23, with estimates from $7.16 to $11.97 from 11 analysts.

    What revenue do analysts expect from Krystal Biotech next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $497.46M, with estimates from $494.00M to $500.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $634.85M, with estimates from $595.30M to $680.80M.

    How many analysts cover KRYS?

    12 analysts rate Krystal Biotech stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.